December 2022

Sementis are grateful and proud to have the support of DMTC Ltd to advance research and development of our novel SCV viral vector vaccine platform technology.

The ambition for the Sementis Ltd technology is to provide an Australian-owned vaccine platform technology suitable for adaptation to known and emerging disease pathogens and thus contribute to sovereign vaccine capability and preparedness.

We look forward to furthering the collaboration with our long term research partners at University of South Australia as well as building upon our collaborations with The Australian National University and Monash University.

Read more at https://www.dmtc.com.au/news/key-steps-to-advance-vaccine-manufacturing-technology/